Joshua Aiello reports 15,000 RSU award for Orchestra BioMed (OBIO)

Rhea-AI Filing Summary

Joshua Aiello, Principal Accounting Officer at Orchestra BioMed Holdings, Inc. (OBIO), reported an award of 15,000 restricted stock units (RSUs) on August 7, 2025. Each RSU represents a contingent right to one share of common stock and the grant lists a $0 per-share price. The RSUs vest in three tranches over three years: 33.33% vest 24 months after the grant date, 33.33% vest 30 months after the grant date, and 33.34% vest 36 months after the grant date, subject to continuous service. The Form 4 shows 19,329 shares as beneficially owned following the reported transaction and is signed by an attorney-in-fact on August 8, 2025.

Insights

Securities Analyst

TL;DR: Routine executive equity grant of 15,000 RSUs to the company’s principal accounting officer; disclosure appears standard and non-material.

The filing documents a time‑based equity award to align the reporting person with shareholder interests. The award is structured as RSUs at $0 with a clearly defined three‑year vesting schedule. The Form 4 also reports 19,329 shares beneficially owned after the grant. There is no indication of accelerated vesting, sales, or related-party transfers. From a market‑impact perspective, the grant is typical compensation disclosure without immediate dilution or cash transfer.

Corporate Governance Expert

TL;DR: Compensation disclosure follows standard Form 4 practice; vesting terms are time‑based and subject to continued service.

The report identifies the recipient as Principal Accounting Officer and provides the grant date, unit count, and precise vesting milestones, which supports transparency around executive incentives. The signature by an attorney‑in‑fact is noted and the filing includes the resulting beneficial ownership total. Absent additional context on company capitalization or related insider transactions, this appears to be a routine equity compensation event rather than a governance concern.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Aiello Joshua

(Last) (First) (Middle)

C/O ORCHESTRA BIOMED HOLDINGS, INC.

150 UNION SQUARE DRIVE

(Street)

NEW HOPE PA 18938

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Orchestra BioMed Holdings, Inc. [ OBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Principal Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001 per share ("Common Stock")	08/07/2025		A(1)		15,000	A	$0	19,329	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents an award of restricted stock units ("RSUs") to the Reporting Person on August 7, 2025 (the "Grant Date"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest over a three-year period as follows: (i) 33.33% of the shares will vest 24 months after the Grant Date, (ii) 33.33% of the shares will vest 30 months after the Grant Date, and (iii) 33.34% of the shares will vest 36 months after the Grant Date, subject to the Reporting Person's continuous service through such dates.

	/s/ Andrew Taylor, Attorney-in-Fact	08/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Joshua Aiello report on Form 4 (OBIO)?

He reported an award of 15,000 restricted stock units (RSUs) granted on August 7, 2025.

How do the RSUs awarded to the OBIO officer vest?

The RSUs vest over three years: 33.33% at 24 months, 33.33% at 30 months, and 33.34% at 36 months after the grant date, subject to continuous service.

What is the beneficial ownership after the reported transaction in the OBIO Form 4?

The Form 4 reports 19,329 shares as beneficially owned following the reported transaction.

What price was reported for the RSU award on the OBIO Form 4?

The transaction lists a price of $0, reflecting that the award is an RSU grant rather than a purchase.

When was the Form 4 transaction dated and who signed the filing?

The transaction date is August 7, 2025, and the Form 4 is signed by Andrew Taylor, Attorney‑in‑Fact, dated August 8, 2025.